Publications

I am acknowledged as providing medical writing and/or editing support on the following manuscripts:

Urothelial carcinoma
Nivolumab
Primary papers:
Renal cell carcinoma
Sunitinib
Primary papers:
  • Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516–2524. doi:10.1001/jama.295.21.2516
    http://jama.jamanetwork.com/article.aspx?articleid=202955
  • Bello CL, Sherman L, Zhou J, et al. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs 2006;17:353–358.
    http://www.ncbi.nlm.nih.gov/pubmed/16520665
  • Houk BE, Bello CL, Kang D, Amantea M. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res 2009;15:2497–2506. doi: 10.1158/1078-0432.CCR-08-1893.
    http://clincancerres.aacrjournals.org/content/15/7/2497.long
Review papers:
Temsirolimus
Review papers:
  • Porta C, Tortora G, Larkin JMG, Hutson TE. Management of poor-risk metastatic renal cell carcinoma: current approaches, the role of temsirolimus and future directions. Future Oncology 26 November, 2015 [ePub ahead of print]. doi:10.2217/fon.15.313
    http://www.futuremedicine.com/doi/pdf/10.2217/fon.15.313
  • Stenner-Liewen F, Grünwald V, Greil R, Porta C. The clinical potential of temsirolimus in second or later lines of treatment for metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2013;13:1021–1033. doi: 10.1586/14737140.2013.833684
    http://www.ncbi.nlm.nih.gov/pubmed/24024788
Biomarkers
Review papers:
Other RCC
Review papers:
Breast cancer
Primary papers:
  • Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008;26:1810-6. doi: 10.1200/JCO.2007.14.5375
    http://jco.ascopubs.org/content/26/11/1810.full.pdf+html
GIST
Primary papers:
  • Komatsu Y, Ohki E, Ueno N, et al. Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor. Jpn J Clin Oncol 2015;45:1016–1022. doi: 10.1093/jjco/hyv126
    http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622169/
Neuroendocrine tumours
Primary papers:
Review paper:
Antiangiogenic therapy – imaging
Primary papers:
Secondary paper:
  • Lassau N, Bonastre J, Kind M, et al. Validation of dynamic contrast-enhanced ultrasound in predicting outcomes of antiangiogenic therapy for solid tumors. The French Multicenter Support for Innovative and Expensive Techniques Study. Invest Radiol 2014;49:794–800. doi: 10.1097/RLI.0000000000000085
    http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4222794/
Dacomitinib
Primary papers:
  • Bello CL, LaBadie RR, Ni G, Boutros T, McCormick C, Ndongo MN. The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers. Cancer Chemother Pharmacol 2012;69:991–997. doi: 10.1007/s00280-011-1793-7
    http://www.ncbi.nlm.nih.gov/pubmed/22147075
  • Jänne PA, Ou SH, Kim DW, et al. Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. Lancet Oncol 2014;15:1433–1441. doi: http://dx.doi.org/10.1016/S1470-2045(14)70461-9
    http://www.ncbi.nlm.nih.gov/pubmed/25456362
  • Park K, Cho BC, Kim D-W, et al. Safety and efficacy of dacomitinib in Korean patients with kras wild-type advanced non–small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial. J Thorac Oncol 2014;9:1523–1531. doi: 10.1097/JTO.0000000000000275
    http://www.sciencedirect.com/science/article/pii/S1556086415307097
  • Takahashi T, Boku N, Murakami H, et al. Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors. Invest New Drugs 2012;30:2352–2363. doi: 10.1007/s10637-011-9789-z
    http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523469/
Malaria
Primary papers:
Review papers: